Target Price | $8.15 |
Price | $2.38 |
Potential |
242.60%
register free of charge
|
Number of Estimates | 13 |
13 Analysts have issued a price target Editas Medicine, Inc. 2025 .
The average Editas Medicine, Inc. target price is $8.15.
This is
242.60%
register free of charge
$15.00
530.25%
register free of charge
$1.00
57.98%
register free of charge
|
|
A rating was issued by 18 analysts: 9 Analysts recommend Editas Medicine, Inc. to buy, 8 to hold and 1 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Editas Medicine, Inc. stock has an average upside potential 2025 of
242.60%
register free of charge
|
Dec '23 |
2024 Estimates |
|
---|---|---|
Revenue Million $ | 78.12 | 42.90 |
296.35% | 45.08% | |
EBITDA Margin | -208.81% | -489.73% |
81.26% | 134.54% | |
Net Margin | -213.43% | -485.64% |
84.12% | 127.54% |
16 Analysts have issued a sales forecast Editas Medicine, Inc. 2024 . The average Editas Medicine, Inc. sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an Editas Medicine, Inc. EBITDA forecast 2024. The average Editas Medicine, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
7 Editas Medicine, Inc. Analysts have issued a net profit forecast 2024. The average Editas Medicine, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '23 |
2024 Estimates |
|
---|---|---|
Earnings Per Share $ | -2.02 | -2.52 |
37.07% | 24.75% | |
P/E | negative | |
EV/Sales | negative |
7 Analysts have issued a Editas Medicine, Inc. forecast for earnings per share. The average Editas Medicine, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the Editas Medicine, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Editas Medicine, Inc....
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.